Oncoinvent ASA
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Oncoinvent ASA is a Norwegian biotechnology company developing targeted radiopharmaceuticals to provide innovative treatments for cancer patients worldwide.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 07:00 |
Regulatory News Service
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® i…
|
Norwegian | 230.2 KB | |
| 2025-06-18 07:00 |
Regulatory News Service
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® i…
|
Norwegian | 7.2 KB | |
| 2025-05-14 12:39 |
Regulatory News Service
Minutes from the annual general meeting 2025
|
English | 1.5 MB | |
| 2025-05-14 12:39 |
Regulatory News Service
Minutes from the annual general meeting 2025
|
English | 1.6 KB | |
| 2025-04-30 11:41 |
Regulatory News Service
Notice of Annual General Meeting
|
English | 374.9 KB | |
| 2025-04-30 11:41 |
General Meeting Notice
Notice of Annual General Meeting
|
English | 3.4 KB | |
| 2025-04-28 18:22 |
Annual Report
Oncoinvent ASA: Annual Report 2024
|
English | 7.5 MB | |
| 2025-04-28 18:22 |
Annual Report
Oncoinvent ASA: Annual Report 2024
|
English | 3.0 KB | |
| 2025-04-28 06:05 |
Regulatory News Service
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
|
English | 142.6 KB | |
| 2025-04-28 06:05 |
Regulatory News Service
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
|
English | 3.3 KB | |
| 2025-04-28 06:00 |
Regulatory News Service
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with…
|
English | 152.8 KB | |
| 2025-04-28 06:00 |
Regulatory News Service
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with…
|
English | 5.3 KB | |
| 2025-04-28 05:45 |
Regulatory News Service
Financial calendar
|
English | 607 bytes | |
| 2025-03-25 06:00 |
Regulatory News Service
Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to …
|
English | 3.8 KB | |
| 2025-03-05 09:57 |
Directors' Dealings
Oncoinvent ASA: Mandatory notification of trade
|
English | 1.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Toleranzia AB | Sweden | TOL | |
|
Transgene | France | TNG | |
|
Tvardi Therapeutics Inc. | United States of America | TVRD | |
|
Ulisse Biomed | Italy | UBM | |
|
Univo Pharmaceuticals Ltd. | Israel | UNVO-M | |
|
Urteste S.A. | Poland | URT | |
|
Valbiotis | France | ALVAL | |
|
VALIRX PLC | United Kingdom | VAL | |
|
Vaxxa AB | Sweden | VAXXA | |
| Vision Sigma Ltd. | Israel | VISN |